Market news

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com

Perspective Therapeutics (CATX) has signed a clinical trial collaboration with Merck (MRK) for the p

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place Novemb

Perspective Therapeutics is rated Strong Buy on durable radiopharmaceutical data, $237M cash runway, and key 2026 catalysts. Click here to read more.

Perspective Therapeutics (CATX) has an average rating of buy and mean price target of $12.47, accord

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

Perspective Therapeutics' (CATX) NET program to potentially treat neuroendocrine tumors may be advan

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacityVMT-α-NET study update accepted for oral presentation at ESMO 2026VMT01 melanoma and PSV359 FAP-α clinical programs continue to advanceApproximately $237 million in cash, cash equivalents, and short-term investments as of June 3

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspect

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

European orphan medicinal product designation granted for [²¹²Pb]VMT-α-NET for the treatment of GEP-NETs[²¹²Pb]VMT-α-NET is being evaluated in an ongoing Phase 1/2a study in patients with SSTR2-positive neuroendocrine tumors; interim clinical data support [212Pb]VMT-α-NET’s potential to provide significant benefit relative to approved therapies for European patients living with GEP-NETs Designation provides development and potential commercial incentives to support the advancement of [²¹²Pb]VMT-

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, S

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programsSEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer. The Company also announc

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. An expanding radiopharmaceutical pipeline, now stretching into a new brain tumor indication, is strengthening the company’s long-term growth narrative. On July 1, 2026, Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) updated its corporate presentation to highlight progress across its […]